In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Chronic hepatitis C virus infection in thalassemia major: a new cardiovascular risk factor?

Session Poster Session 2

Speaker Antonella Meloni

Event : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : A Pepe (Pisa,IT), L Pistoia (Pisa,IT), N Giunta (Palermo,IT), I Fotzi (Firenze,IT), M Benni (Bologna,IT), A Barone (Parma,IT), S Macchi (Ravenna,IT), F Pasin (Roma,IT), G Peritore (Palermo,IT), P Fina (Roma,IT), V Positano (Pisa,IT), A Meloni (Pisa,IT)

Authors:
A. Pepe1 , L. Pistoia1 , N. Giunta2 , I. Fotzi3 , M. Benni4 , A. Barone5 , S. Macchi6 , F. Pasin7 , G. Peritore2 , P. Fina7 , V. Positano1 , A. Meloni1 , 1Fondazione G. Monasterio CNR-Regione Toscana - Pisa - Italy , 2Ospedale Civico - Palermo - Italy , 3Ospedale “Meyer” - Firenze - Italy , 4Policlinico S. Orsola “L. e A. Seragnoli” - Bologna - Italy , 5University Hospital of Parma - Parma - Italy , 6Santa Maria delle Croci Hospital - Ravenna - Italy , 7Ospedale S. Pertini - Roma - Italy ,

Topic(s):
Myocardial Disease – Epidemiology, Prognosis, Outcome

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 313-314

Background: Hepatitis C virus (HCV) infection is associated with a number of important extrahepatic manifestations.

Aim: The aim of this multicentric study was to assess the relationship between HCV infection and some traditional cardiovascular risk factors (CRF) and its predictive value and cardiovascular complications (CC) in thalassemia major (TM) patients.

Methods: We considered 827 TM patients (435 F) consecutively enrolled in the Myocardial Iron Overload in Thalassemia (MIOT) network.

At the baseline assessment mean age of the patients, all free of CC, was 29.65±8.89 years and a categorization in 4 groups was performed: negative patients (group 0), patients who spontaneously cleared HCV (group 1), patients who eradicated the virus after treatment with antiviral therapy attaining a sustained virological response-SVR (group 2), and patients with chronic HCV infection (group 3).

Results: Patients in group 0 were significantly younger than patients in all the other three groups (P<0.0001) and had a significant lower frequency of diabetes than patients in group 3 (3.6% vs 11.0%; P=0.006).

Patients were followed-up for 79.53±28.71 months and 84 cardiovascular events (42 arrhythmias, 29 heart failure, and 13 vascular diseases) were registered. Table 1 shows the results of the univariate Cox regression analysis. Patients with chronic HCV infection had a significant higher risk of developing CC than negative patients.

Conclusions: HCV chronic infection is associated with a significant higher risk of CC in TM patients and, as a consequence, it should be analyzed as a systemic disease in which extrahepatic consequences increase the weight of its pathological burden.

Table 1
N (%) in GroupN (%) with CCUnivariate analysis
HR (95% CI)P
HCV group
  Group 0290 (35.1)19 (6.6)Reference
  Group 1241 (29.1)24 (10.0)1.42 (0.78–2.59)0.258
  Group 243 (5.2)5 (11.6)1.84 (0.69–4.93)0.225
  Group 3253 (30.6)36 (14.2)2.18 (1.25–3.79)0.006

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are